NewsBenzingaBarclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $32 Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $32 Benzinga 2026.11.05 19:13 (GMT+0) Open on Benzinga Other news UBS Maintains Buy on CDW, Raises Price Target to $195 UBS Maintains Buy on Addus HomeCare, Raises Price Target to $160 UBS Maintains Neutral on Qualcomm, Lowers Price Target to $180 UBS Maintains Neutral on HubSpot, Lowers Price Target to $240 UBS Maintains Buy on Edwards Lifesciences, Raises Price Target to $118 UBS Maintains Buy on Amplitude, Raises Price Target to $22
